NRNP 6665 Final Exam Test Questions
1. Question 18: A. Dissociative disorders
Christine is a 9-year-old female B. Post-traumatic stress disorder
who presents for care after hav- C. Impulse-control disorder
ing been placed in the local fos- D. Attachment disorder
ter care system. She has been in
and out of foster care for the last
4 years after her parents were
killed in an automobile accident.
Christine has been placed in a
variety of homes and residential
care facilities. The PMHNP recog-
nizes that Christine is at high risk
for:
2. Question 7: A. Caylee is at high risk for suicide and precautions should
Caylee is a 5-year-old girl who is be taken
referred for evaluation by child B. The hallucinations are consistent with brief psychotic
protective services. She was re- disorder or schizophrenia
cently removed from her biolog- C. The history and reported symptoms are typical of de-
ical family and placed in fos- pressive disorder in young children
ter care, as her home envi- D. This is a common situation when prepubertal children
ronment was reportedly unsafe are removed from the biological parents regardless of
due to conditions of extreme how dysfunctional they are
neglect. Her foster mother re-
ports that Caylee is very quiet
and withdrawn and always ap-
pears sad and disinterested in
her surroundings; however, she
becomes very irritable when any-
thing unexpected or unplanned
occurs. The foster mother be-
came very concerned when it ap-
, NRNP 6665 Final Exam Test Questions
peared that Caylee was hallu-
cinating. The PMHNP considers
that:
3. Question 2: A. There is a > 50% likelihood that Debi's younger sibling
Debi is a 15-year-old girl who will develop depressive symptoms
is currently being treated for B. The mean length of major depressive episode in ado-
depression. Her parents have lescents is 4 months
been very proactive and in- C. 20 to 40% of adolescents who have major depressive
volved in her care, and Debi has disorder will develop bipolar I within 5 years
achieved remission 2 months af- D. Adolescent-onset depression typically need long-term
ter beginning treatment with a pharmacologic management to prevent relapses
combination of pharmacothera-
py and cognitive behavioral ther-
apy. While counseling Debi's par-
ents about important issues in
management, the PMHNP advis-
es that:
4. Agomelatine Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxi-
ety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase
to 50 mg/day at bedtime
5. Amitriptyline (Elavil) Tricyclic antidepressant.
6. Aripiprazole (Abilify) Treatment for depression. Atypical antipsychotic.
"Dopamine stabilizer". Dopamine receptor antagonist
in high concentration and also stimulates increase of
, NRNP 6665 Final Exam Test Questions
dopamine in low concentrations. Side effects: insomnia,
akathisia.
7. Brexpiprazole (Rexulti) Treatment for depression. Atypical antipsychotic
8. Bupropion (Wellbutrin) Antidepressant and smoking cessation aid, It can treat
depression and help people quit smoking. It can also
prevent depression caused by seasonal affective disorder
(SAD).
9. Citalopram (Celexa) Antidepressant, SSRI: 20-40 mg qd.
10. Clomipramine (Anafranil) -Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradren-
aline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking
the serotonin reuptake pump (transporter), -Desensiti-
zation of serotonin receptors, especially serotonin 1A re-
ceptors
-Increases noradrenergic neurotransmission by blocking
the norepinephrine reuptake pump (transporter), -De-
sensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in
the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of
the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive
disorder (OCD) (ages 10 and older)
*Off-Label for Pediatric Use: Depression, Severe and
treatment-resistant, depression, Cataplexy syndrome,
, NRNP 6665 Final Exam Test Questions
Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
11. Cyamemazine (Tercian) Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyra-
midal side effects (5-HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine,
dopamine 2 antagonist, serotonin dopamine antago-
nist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, in-
cluding mood disorders and personality disorders
(short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
12. Desiprimine (Norpramine)
1. Question 18: A. Dissociative disorders
Christine is a 9-year-old female B. Post-traumatic stress disorder
who presents for care after hav- C. Impulse-control disorder
ing been placed in the local fos- D. Attachment disorder
ter care system. She has been in
and out of foster care for the last
4 years after her parents were
killed in an automobile accident.
Christine has been placed in a
variety of homes and residential
care facilities. The PMHNP recog-
nizes that Christine is at high risk
for:
2. Question 7: A. Caylee is at high risk for suicide and precautions should
Caylee is a 5-year-old girl who is be taken
referred for evaluation by child B. The hallucinations are consistent with brief psychotic
protective services. She was re- disorder or schizophrenia
cently removed from her biolog- C. The history and reported symptoms are typical of de-
ical family and placed in fos- pressive disorder in young children
ter care, as her home envi- D. This is a common situation when prepubertal children
ronment was reportedly unsafe are removed from the biological parents regardless of
due to conditions of extreme how dysfunctional they are
neglect. Her foster mother re-
ports that Caylee is very quiet
and withdrawn and always ap-
pears sad and disinterested in
her surroundings; however, she
becomes very irritable when any-
thing unexpected or unplanned
occurs. The foster mother be-
came very concerned when it ap-
, NRNP 6665 Final Exam Test Questions
peared that Caylee was hallu-
cinating. The PMHNP considers
that:
3. Question 2: A. There is a > 50% likelihood that Debi's younger sibling
Debi is a 15-year-old girl who will develop depressive symptoms
is currently being treated for B. The mean length of major depressive episode in ado-
depression. Her parents have lescents is 4 months
been very proactive and in- C. 20 to 40% of adolescents who have major depressive
volved in her care, and Debi has disorder will develop bipolar I within 5 years
achieved remission 2 months af- D. Adolescent-onset depression typically need long-term
ter beginning treatment with a pharmacologic management to prevent relapses
combination of pharmacothera-
py and cognitive behavioral ther-
apy. While counseling Debi's par-
ents about important issues in
management, the PMHNP advis-
es that:
4. Agomelatine Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxi-
ety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase
to 50 mg/day at bedtime
5. Amitriptyline (Elavil) Tricyclic antidepressant.
6. Aripiprazole (Abilify) Treatment for depression. Atypical antipsychotic.
"Dopamine stabilizer". Dopamine receptor antagonist
in high concentration and also stimulates increase of
, NRNP 6665 Final Exam Test Questions
dopamine in low concentrations. Side effects: insomnia,
akathisia.
7. Brexpiprazole (Rexulti) Treatment for depression. Atypical antipsychotic
8. Bupropion (Wellbutrin) Antidepressant and smoking cessation aid, It can treat
depression and help people quit smoking. It can also
prevent depression caused by seasonal affective disorder
(SAD).
9. Citalopram (Celexa) Antidepressant, SSRI: 20-40 mg qd.
10. Clomipramine (Anafranil) -Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradren-
aline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking
the serotonin reuptake pump (transporter), -Desensiti-
zation of serotonin receptors, especially serotonin 1A re-
ceptors
-Increases noradrenergic neurotransmission by blocking
the norepinephrine reuptake pump (transporter), -De-
sensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in
the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of
the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive
disorder (OCD) (ages 10 and older)
*Off-Label for Pediatric Use: Depression, Severe and
treatment-resistant, depression, Cataplexy syndrome,
, NRNP 6665 Final Exam Test Questions
Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
11. Cyamemazine (Tercian) Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyra-
midal side effects (5-HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine,
dopamine 2 antagonist, serotonin dopamine antago-
nist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, in-
cluding mood disorders and personality disorders
(short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
12. Desiprimine (Norpramine)
